Clinical Trials Logo

Clinical Trial Summary

Diarrhoea caused by Shigella (shigellosis) is of major public health importance. However, there are no licensed Shigella vaccines in routine use, with several candidates still in various stages of clinical development. Shigella human infection studies (HIS) have played a key role in vaccine development. These models also allow for the evaluation of immunity and other non-immunological parameters that are important to understand resistance and/or susceptibility to disease. This is particularly useful in individuals from endemic areas with varying levels of prior exposure and immunity to Shigella. Thus, establishing a Shigella HIS would enable the testing of interventions such as vaccines in a population that would most benefit from a subsequent vaccine and has potential to accelerate vaccine development. Here, the goal is to successfully establish a Shigella sonnei human infection model in Kenyan adults. This will be achieved by conducting dose-finding and dose verification Shigella studies that safely and reproducibly induce ≥60% attack rates. In this study, investigators aim to use Shigella HIS in healthy adults to develop a model as a platform to test vaccines, to study immune responses identifying potential correlates of infection, and non-immunological factors mediating and influencing susceptibility to disease. To achieve this, the study will be carried out in two phases over a period of 12-14 months. Phase A will enroll (N=up to 40 volunteers) and Phase B will enroll an additional (N=30 volunteers). To be eligible to receive a dose of 53G, volunteers must pass the screening visit. Investigators will vary the dose of bacteria in individuals enrolled for challenge to identify the dose needed to cause ≥60% shigellosis (attack rate) (Phase A) followed by testing and demonstrate the reproducibility of the model (Phase B). Thus, the main outcomes of the study will be: (1) optimisation of bacterial dose for infection success (≥60% attack rate); and (2) safety.


Clinical Trial Description

This is a Phase 1 dose finding and dose verification study which will be used to determine the dose of S. sonnei 53G that induces the primary outcome in approximately ≥60% of Kenyan adult volunteers. This study will occur in two phases, Phase A (dose-finding) with up to 40 volunteers challenged with 53G and Phase B (dose verification) with N=30 volunteers planned to be administered 53G. Based on previously published data using this model, 1,500 colony-forming units (CFU) will be the dose administered to the first cohort. Dosing of subsequent cohorts will depend on results of the previous cohort. If a lower-than-expected attack rate (AR) occurs, the dose for the next cohort will be increased by 500 CFU. Conversely, if the AR is higher than expected the dose for the next cohort will be decreased by 500 CFU. Cohorts of volunteers will continue to be challenged until either; a dose that reproducibly causes infection in at least 60% of volunteers; safety precludes continuing (>90% AR at 500 CFU) or futility (an AR of 60% is unable to be achieved, even with a 3000 CFU dose). It may take more or less than 3 dose-finding groups to find the optimal dose for which the primary outcome (shigellosis) is achieved in approximately ≥60% of the volunteers and thus the total number of volunteers enrolled in both phases may be less or more than N=60. Once the optimal dose is established in Phase A, that dose will be carried forward for verification in Phase B. For Phase B, dose verification groups of 30 volunteers (2 cohorts of 15 volunteers per cohort) will be conducted to verify the AR with the chosen dose. The dose finding and verification stages will be done in a staggered fashion in case the dose needs to be adjusted, resulting in approximately 5 cohorts to be enrolled over time. Allocation into the groups will be on "first come first served basis" with no randomization occurring for enrolment in any of the cohorts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05959616
Study type Interventional
Source University of Oxford
Contact
Status Not yet recruiting
Phase Phase 1
Start date October 1, 2024
Completion date November 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT02797236 - SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT04056117 - A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Phase 1/Phase 2
Completed NCT02445963 - Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Phase 1
Not yet recruiting NCT05961059 - InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia Phase 1
Completed NCT00485134 - Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Phase 1/Phase 2
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT02034500 - Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Phase 1
Completed NCT01509846 - Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Phase 1
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Withdrawn NCT01399424 - Shigella Sonnei OSPC-rDT Conjugate Vaccine Phase 1
Completed NCT00800930 - Therapeutic Induction of Endogenous Antibiotics Phase 2
Completed NCT00368316 - Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Phase 3
Recruiting NCT05182749 - Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis Phase 1/Phase 2
Completed NCT02388009 - Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Phase 1
Completed NCT02017899 - A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. Phase 1
Completed NCT01069471 - Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Phase 1
Completed NCT02646371 - Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Phase 2
Recruiting NCT05156528 - Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Phase 3
Completed NCT03854929 - Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery Phase 4
Recruiting NCT05121974 - Tebipenem Trial in Children With Shigellosis Phase 2